What changed for Glaucoma
A plain English summary of what recently moved in the public data Voxsanity tracks for Glaucoma. Updated from government registries. Not medical advice.
How to read these changes: every figure on this page is the difference between two snapshots of what Voxsanity had tracked on each date. Voxsanity only began taking daily snapshots in July 2026 and is still ingesting the public registries, so a rise here is mostly our own coverage expanding rather than new research appearing. Read it as our tracked coverage growing, not as a claim about real-world research changing this fast: it overstates how much actually changed.
Comparing the two most recent snapshots, 27 July 2026 and 28 July 2026.
- Trials recruiting worldwide 147 to 150 (+3)
- Trials on record 1,668 to 1,655 (-13)
Newly subsidised on the PBS
No PBS-reviewed medicines are tracked for Glaucoma yet, so new PBS listings cannot be reported for it. This is a gap in what Voxsanity has mapped, not a statement that no medicines are subsidised — check the PBS directly.
Past updates
Tracking began in July 2026. Month on month changes will appear here once a second month of data has been recorded. Until then, the comparison above shows the most recent movement.
Recent trend
Weekly, most recent weeks (fills out to a monthly trend as history grows).
Recent trial results
The 30 most recent of 81 trials tracked for Glaucoma that have reported results to a public registry.
AI generated results summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
-
NCT02928289 · results posted 24 September 2025
According to the results reported on ClinicalTrials.gov, this trial compared two procedures used in glaucoma management: a surgical procedure called VISCO360 ab interno canaloplasty, and a laser procedure called Selective Laser Trabeculoplasty (SLT). The trial set out to measure changes in eye pressure (measured in millimetres of mercury, or mm Hg — a standard unit for pressure) over 12 months. A total of 17 people started the trial — 7 in the surgery group and 10 in the laser group. The reported data shows that none of the participants were recorded as having formally completed the trial, whi...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT02390284 · results posted 26 August 2025
According to the results reported on ClinicalTrials.gov, this trial (NCT02390284) was set up to look at three groups of people: those with an abnormal eye signal test result who were untreated, those with an abnormal eye signal test result who received treatment, and those with a normal eye signal test result. The trial was measuring the health of the nerve fibres at the back of the eye (the retina), along with electrical signals produced by the retina in response to visual patterns. A total of 28 participants were enrolled in the "Normal" group, of whom 19 completed the study and 9 did not. N...
-
NCT04445519 · results posted 30 May 2025
According to the results reported on ClinicalTrials.gov, this trial (NCT04445519) enrolled 691 participants across three groups: 30 people received a lower-dose eye drop called NCX 470 at 0.065% concentration, 328 received a higher-dose NCX 470 at 0.1% concentration, and 333 received a comparison eye drop called latanoprost 0.005% (an already-available glaucoma drop). The trial was measuring changes in eye pressure — formally called intraocular pressure, or IOP — which is the fluid pressure inside the eye. After an early check at two weeks, the lower-dose NCX 470 group was discontinued as plan...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT03560609 · results posted 29 January 2025
According to the results reported on ClinicalTrials.gov, this trial (NCT03560609) enrolled two groups of participants: people with a condition called keratoconus (a shape change in the cornea, the clear front of the eye) and people with glaucoma (a condition involving pressure-related damage to the eye). In total, only 3 people were recorded as having started the trial — all in the keratoconus group — and no participants were recorded as having joined the glaucoma group. None of the participants were recorded as having completed the trial. The trial was designed to measure changes in eye tiss...
-
NCT04360174 · results posted 1 October 2024
According to the results reported on ClinicalTrials.gov, this trial (NCT04360174) enrolled 19 people in total, split across four groups (called cohorts) of roughly four to five people each. All 19 participants completed the study — none dropped out. The trial was looking at two main things: any eye-related unwanted events that occurred during treatment, and changes in eye pressure (a measure called intraocular pressure, or IOP — essentially how much fluid pressure is inside the eye) after 12 weeks compared to the start of the study. The reported data shows that the number of eye-related unwan...
-
NCT04468633 · results posted 5 September 2024
According to the results reported on ClinicalTrials.gov, this trial (NCT04468633) enrolled 76 people with glaucoma — 37 received a device called the Baerveldt 350 implant and 39 received a device called the Ahmed ClearPath 350 implant. These are small tubes surgically placed in the eye to help drain fluid and reduce pressure. All 39 people in the Ahmed ClearPath group completed the study, while 4 of the 37 in the Baerveldt group did not. The trial was primarily measuring the pressure inside the eye (called intraocular pressure, or IOP) over time, and how many participants experienced a complic...
-
NCT03861169 · results posted 14 August 2024
According to the results reported on ClinicalTrials.gov, this trial involved 209 people who had the OMNI® Surgical System procedure, a device used in eye surgery aimed at lowering pressure inside the eye (known as intraocular pressure, or IOP — high IOP is associated with glaucoma). The trial tracked participants over 12 months, measuring two main things: how much their eye pressure changed when they were not taking any eye-pressure-lowering medications, and how many of those medications they were using before versus after the procedure. Of the 209 people who started, 149 completed the trial,...
-
NCT05674890 · results posted 9 August 2024
According to the results reported on ClinicalTrials.gov, this trial (NCT05674890) compared two types of visual field tests — a standard clinic-based machine called the Humphrey Field Analyser (HFA) and a newer virtual reality headset system (SSVR). A total of 98 people started the trial (40 in one group, 58 in the other), and 81 completed it. The trial measured how similar the results from the two devices were, by looking at three technical readings from each test: "mean deviation" (how much a person's overall vision differs from what's typical for their age), "pattern standard deviation" (how...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT02507687 · results posted 10 May 2024
According to the results reported on ClinicalTrials.gov, this trial compared two approaches to lowering eye pressure in people with glaucoma or raised eye pressure. One approach used a procedure called selective laser trabeculoplasty (SLT — a type of laser treatment applied to the eye's drainage area), and the other used a small implant called Bimatoprost SR 10 µg, which slowly releases a pressure-lowering medicine inside the eye. The trial was run in two stages; the main reported results come from Stage 2, which enrolled 183 participants (92 in one group, 91 in the other). Each participant ha...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT04629521 · results posted 26 April 2024
According to the results reported on ClinicalTrials.gov, this trial (NCT04629521) enrolled 54 participants who had undergone cataract surgery combined with insertion of a small eye device called the CyPass micro-stent. Of those, 46 completed the study and 8 did not. The trial was a long-term follow-up study that tracked participants for up to nine years after their original surgery. It measured two main things: whether participants experienced any eye-related adverse events (unexpected medical problems affecting the eye), including any that could threaten sight; and the health of a layer of ce...
-
NCT04200651 · results posted 31 January 2024
According to the results reported on ClinicalTrials.gov, this trial (NCT04200651) enrolled 24 participants in total — 14 in the DEXTENZA® group (a slow-release steroid insert placed in the eye) and 10 in the Prednisolone Acetate 1% eye drop group. Of those, 11 and 5 participants respectively completed the study. The trial was measuring changes in eye pressure and vision sharpness after eye surgery, as well as tracking unwanted events, changes in glaucoma medications, and signs of swelling at the back of the eye (a condition called cystoid macular oedema). The reported data shows the following...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT05022004 · results posted 18 January 2024
According to the results reported on ClinicalTrials.gov, this trial enrolled 597 people in total — 297 in the BRIN-20-01 group and 300 in the Azopt® group. The vast majority completed the study (287 and 289 respectively). The trial was measuring eye pressure (called intraocular pressure, or IOP — the fluid pressure inside the eye) in both eyes, comparing the two treatments at several points in time. Azopt® is an already-approved eye-pressure medicine, and BRIN-20-01 appears to be a version being compared against it. The reported data shows that at the start of the study, average eye pressure...
-
NCT05790408 · results posted 15 November 2023
According to the results reported on ClinicalTrials.gov, this trial (NCT05790408) enrolled 10 people in a single study group. The trial was looking at a type of eye surgery related to glaucoma — specifically, it was measuring whether a surgical procedure could lower eye pressure (measured without eye-drop medications) by at least 20% compared to each person's pressure before the operation. The trial also looked at whether a special imaging tool used during surgery, called intraoperative OCT (a type of real-time internal scanning), could successfully capture images of the surgical area during t...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT04615403 · results posted 26 September 2023
According to the results reported on ClinicalTrials.gov, this trial (NCT04615403) enrolled 33 participants, all of whom were in a single group that underwent a lens implantation and/or exchange procedure. The trial was primarily measuring ocular (eye-related) safety — specifically, how many participants experienced any unwanted medical events in the eye being treated, both during and after the procedure. Thirty-two of the 33 participants completed the study, with one person not completing it (the reason was not reported in the data provided). The reported data shows that the main outcome bein...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT04949802 · results posted 21 September 2023
According to the results reported on ClinicalTrials.gov, this trial enrolled 15 participants in a single group who received a laser treatment. The trial was measuring changes in eye pressure (known as intraocular pressure, or IOP — the pressure inside the eye) after the laser procedure. Of the 15 people who started, 12 completed the study and 3 did not finish. The reported data shows that, at the end of the study, the average eye pressure across participants was 12.7 mmHg (millimetres of mercury — the unit used to measure eye pressure). On average, this represented a reduction of 38.5% compar...
-
NCT03519386 · results posted 14 September 2023
According to the results reported on ClinicalTrials.gov, this trial (NCT03519386) enrolled 590 participants across three groups — Implant Group 1 (200 people), Implant Group 2 (197 people), and a Control Group (193 people). The trial was measuring eye pressure, known as intraocular pressure (IOP), which is the pressure inside the eye measured in millimetres of mercury (mmHg). Specifically, it tracked how much eye pressure changed from each participant's starting level at several points in time — Day 10, Week 6, and Month 3 — with measurements taken at 8am and 10am. The reported data shows tha...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT03697811 · results posted 30 August 2023
According to the results reported on ClinicalTrials.gov, this trial enrolled 107 people who had not been responding well — or were not responding at all — to a common eye-pressure-lowering drop called latanoprost. All participants were given a different eye drop, DE-117 ophthalmic solution 0.002%, and the trial tracked what happened to the pressure inside their eyes (called intraocular pressure, or IOP — a measure of the fluid pressure within the eye) over three months. By the end of the study, 104 people completed the trial and 3 did not. The reported data shows that the main thing being mea...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT04318132 · results posted 24 August 2023
According to the results reported on ClinicalTrials.gov, this trial enrolled 170 people across four groups: 45 people with normal eyes, 47 with retinal conditions, 46 with glaucoma, and 32 with corneal disease. The study was comparing a piece of eye-imaging equipment called the NIDEK Mirante against two already-approved devices — the Optovue RTVue XR Avanti (which uses a scanning technology called OCT to measure layers inside the eye) and the OPTOS P200DTx (which captures wide-field photographs of the back of the eye). The goal was to see how closely the measurements and image quality from the...
-
NCT01956942 · results posted 13 June 2023
According to the results reported on ClinicalTrials.gov, this trial enrolled 69 people with open-angle glaucoma — 38 received a treatment called Micropulse Laser Trabeculoplasty (MLT) and 31 received Selective Laser Trabeculoplasty (SLT). All 69 participants completed the study. The trial was measuring eye pressure (the fluid pressure inside the eye, known as intraocular pressure or IOP), specifically looking at how much each laser procedure changed that pressure compared to where it started. The reported data shows that, on average, eye pressure in the MLT group fell by about 17% from its st...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT04285580 · results posted 8 June 2023
According to the results reported on ClinicalTrials.gov, this trial (NCT04285580) enrolled 37 people in total — 31 received a treatment called Bimatoprost SR 10 μg (a slow-release implant placed in the eye) and 6 received eye drops called LUMIGAN 0.01% (bimatoprost 0.01%). The trial was primarily measuring changes in eye pressure (the fluid pressure inside the eye, known as intraocular pressure or IOP) over time, as well as tracking how many participants experienced any unwanted medical events during the study. The reported data shows that eye pressure went down from the starting point in bot...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT03362931 · results posted 17 May 2023
According to the results reported on ClinicalTrials.gov, this trial enrolled 62 people who had been diagnosed with glaucoma and were treated with a small implanted device called the XEN45 Glaucoma Treatment System. The trial had one group only — everyone received the XEN45 device. The main thing researchers were measuring was how many participants had their eye pressure (a key measure in glaucoma) drop by at least 20% from their starting level after 12 months, while using the same number of eye-pressure-lowering medications or fewer. Of the 62 people who started, 59 completed the trial, and 3...
-
NCT04024072 · results posted 6 March 2023
According to the results reported on ClinicalTrials.gov, this trial involved 495 participants in total — 249 in the "Perrigo Active" group and 246 in the "Reference Active" group. The trial was comparing two versions of an eye drop, measuring changes in eye pressure (called intra-ocular pressure, which is simply the fluid pressure inside the eye) over six weeks. Most participants completed the study: 247 from the Perrigo group and 237 from the Reference group. The reported data shows that the main thing being measured was the average change in eye pressure at four specific time points — at ar...
-
NCT04620135 · results posted 27 February 2023
According to the results reported on ClinicalTrials.gov, this trial enrolled 245 people in total — 122 in one group and 123 in another. The trial compared two different eye drop medicines used to lower the pressure inside the eye (known as intraocular pressure, or IOP). High eye pressure is considered a risk factor for glaucoma, a condition that can damage the optic nerve. One group used Netarsudil 0.02% eye drops (alongside a vehicle, which is an inactive version of the drops), and the other group used Ripasudil 0.4% eye drops. The main thing being measured was average eye pressure at four we...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT04616573 · results posted 1 December 2022
According to the results reported on ClinicalTrials.gov, this trial (NCT04616573) was set up to compare three different surgical approaches for reducing eye pressure in people with glaucoma: a procedure called "ab-interno transluminal viscoelastic delivery with trabeculotomy" using the OMNI Surgical System, a similar but slightly different OMNI procedure without the trabeculotomy step, and implantation of a small device called iStent Inject. The trial planned to measure changes in eye pressure (the force of fluid inside the eye, measured in units called mmHg) without the use of pressure-loweri...
-
NCT03804684 · results posted 29 June 2022
According to the results reported on ClinicalTrials.gov, this trial enrolled 28 healthy participants and 44 people with glaucoma. Of these, 25 healthy participants and 26 people with glaucoma completed the study. The trial was measuring how well two different vision-testing machines agreed with each other when checking how sensitive the eye is to light across the full field of vision. One machine was the Humphrey Visual Field analyser (a standard clinic device) and the other was the VisuALL (a newer device). Sensitivity to light is recorded in units called decibels — in this context, a higher...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT02805257 · results posted 31 May 2022
According to the results reported on ClinicalTrials.gov, this trial enrolled 119 people in total — 60 in the Mitomycin-C group and 59 in the Balanced Salt Solution (BSS) group. Of those, 53 and 52 people respectively completed the study. The trial was measuring eye pressure (the fluid pressure inside the eye) one year after a type of eye surgery, and also tracked eye pressure at six months, the number of eye-drop medications needed, vision scores, and any unintended events that occurred during surgery. The reported data shows that at the one-year mark, the average eye pressure reading was 13....
-
NCT02636946 · results posted 23 February 2022
According to the results reported on ClinicalTrials.gov, this trial enrolled 144 participants in total — 72 in each group. Each participant had one eye treated with a procedure called Selective Laser Trabeculoplasty (SLT), a type of laser treatment, and the other eye treated with a slow-release implant containing a medicine called bimatoprost (Bim SR 15 µg). The trial was measuring eye pressure — specifically the fluid pressure inside the eye, known as intraocular pressure (IOP), measured in millimetres of mercury (mmHg). The main goal was to track how eye pressure changed over time in each ey...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT02691455 · results posted 14 October 2021
According to the results reported on ClinicalTrials.gov, this trial enrolled 45 people with glaucoma — 23 assigned to receive a second aqueous shunt (a small drainage device implanted in the eye) and 22 assigned to receive transscleral cyclophotocoagulation (a laser-based procedure targeting part of the eye that produces fluid). The trial was comparing these two procedures in people whose glaucoma had not been adequately controlled by a previous shunt. The main thing being measured was how many eyes "failed" treatment, based on eye pressure remaining too high or too low, the need for further g...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT03187418 · results posted 8 October 2021
According to the results reported on ClinicalTrials.gov, this trial enrolled 52 participants, all of whom completed the study with no drop-outs. All participants received a procedure called Micropulse Trans-scleral Cyclophotocoagulation (a type of laser treatment applied to the outside of the eye). The trial was measuring eye pressure (known as intraocular pressure, or IOP) as its main focus, along with several other things including how many people needed a repeat treatment, how many eye pressure-lowering medications participants were using, their vision sharpness, and a measure of the optic...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT03452033 · results posted 2 August 2021
According to the results reported on ClinicalTrials.gov, this trial enrolled 87 people in total, split across four groups. Three groups used different strengths of an eye drop called H-1337 (at concentrations of 0.06%, 0.2%, and 0.6%), while a fourth group used a "vehicle" — a version of the drop without the active ingredient, used as a comparison. The trial was measuring eye pressure (called intraocular pressure, or IOP — the fluid pressure inside the eye) and tracking any unwanted health events that occurred during the study. All 87 participants completed the trial. The reported data shows...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
See all 81 reported results for Glaucoma
These are the results as reported to the registry, not medical advice. Verify independently with the trial site and discuss what they mean for you with your doctor.
What is coming
AI generated pipeline summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
According to NIH funding data, a substantial amount of public research funding has been directed toward glaucoma, which reflects that this condition has attracted serious scientific attention. However, the direction of that funding has been falling year on year, meaning researchers and patients should be aware that financial support for new glaucoma studies may be contracting over time. While this...
Not medical advice. Voxsanity republishes public government health data in plain English. These figures describe research and registry activity, not the suitability of any treatment for any person. Trial status can change; always verify current status directly with the trial site and confirm Australian availability with your doctor.